Blossom Health has successfully raised $20 million in seed and Series A funding to introduce an AI “copilot” for psychiatry, as reported exclusively by Fortune. This funding initiative aligns with the growing trend of venture capital investing in AI-driven health technology. Based in New York, Blossom Health aims to establish itself as an AI-native psychiatric platform, asserting that its technological solutions can facilitate the delivery of high-quality mental health care, minimizing the need for additional clinic staffing.
The funding round was spearheaded by Headline, with contributions from Village Global, TA Ventures, Operator Partners, and Correlation Ventures. Notably, this addition brings Headline cofounder Mathias Schilling onto the board.
“Our capital raising strategy has been both intentional and disciplined,” stated founder and CEO John Zhao during the discussion with Fortune, remarking that all funding rounds garnered oversubscription. He underscored the dual nature of capital, describing it as both a powerful asset and a potential burden.
With a background in hyperscale startups, Zhao envisions Blossom Health as a unique opportunity to create a “generational company” within the mental health sector. He points to the increasing necessity for mental health services and anticipates that their importance will expand within the scope of holistic health.
The timing of Blossom’s initiative is seen as a proactive response to the prevailing notion that previous teletherapy and telehealth platforms may have sufficiently addressed digital mental health solutions. Zhao noted that many of these existing services often fall short in adequately addressing psychiatric needs.
Blossom promotes itself as a comprehensive “AI copilot” that enhances clinical decision-making for psychiatrists and automates administrative duties that typically burden clinics. This approach fosters ongoing patient engagement through AI agents that conduct check-ins, identify potential warning signs, and relay pertinent information to clinicians. For example, after a visit for postpartum depression, patients receive follow-up through conversational check-ins, moving away from the older method of using static questionnaires. Most patients using the platform can secure appointments within 48 hours, with many receiving same-day consultations.
Zhao emphasizes that for AI in healthcare to be effective, it must involve clinician collaboration in the development of AI tools. The company has a clinical director and over 100 clinicians testing new features prior to their widespread implementation.
Blossom currently serves hundreds of clinicians who are treating more than 10,000 patients across various states, providing in-network coverage with major insurers and maintaining average copays of approximately $22. This effort targets the estimated one in four U.S. adults who experience mental health conditions each year, with a significant number remaining without treatment.
Zhao's objective is to position Blossom as the “destination of choice” for psychiatric care, with plans to broaden its service coverage beyond the nine states currently catered to and foster deeper relationships with payers while advancing applied AI research and development.
In conclusion, Zhao observes a shift in the healthcare landscape where, traditionally, scale could impede companies; however, Blossom Health aims to demonstrate that growth can amplify the ability to support clinicians and patients more effectively.
Share this story